Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Companies such as Indoor Biotechnologies in Virginia are leveraging cutting-edge scientific techniques to knock out the Fel d 1 protein completely from the cats.
The last several years have marked several attempts to stimulate life sciences startups to pick the Big Apple.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
This week the pharma giant announced a second collaboration agreement with Connecticut-based Arvinas to develop and commercialize its PROTAC estrogen receptor protein degrader.
The company said it has decided to close the study’s open-label and maintenance portions given the inability to satisfy endpoint goals.
The study will also investigate the oral combination with PD-1 inhibitor pembrolizumab in EBV+ metastatic nasopharyngeal carcinoma (RM-NPC).
The U.S. Food and Drug Administration has recently granted Breakthrough Device Designation to two medical device companies, with California-based healthcare tech company Endologix leading the mix.
Biogen’s Aduhelm was approved on June 7, 2021, for Alzheimer’s patients, and the controversy continues to grow.
Biopharma companies from around the globe provide updates on their businesses and pipelines.
Researchers say transplanting fecal microbiota from the mother into the newborn can reverse the risk for Type 1 diabetes for babies who had been exposed to antibiotic treatments early.
The FDA placed a clinical hold on Magenta’s clinical program for acute myeloid leukemia and myelodysplastic syndrome, which made its shares drop nearly 7% this morning.
Genentech announced that the FDA has green-lit the Venclexta classification and azicitidine combination as a Breakthrough Therapy Drug.
PRESS RELEASES
· Supporting the development of its proprietary MIC-Lx Modified Immune Cells technology as a novel approach to reduce lifelong systemic immunosuppression and improve long-term outcomes for transplant recipients · Strengthening MIC-Lx’s regulatory and commercial positioning in Europe
- EUR ~8M grant supports the late-stage clinical development of Omnix’s antimicrobial OMN6 - Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired infections